Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNO155 Alone and in Combination With EGF816 in Advanced Solid Tumors
NCT03114319Phase 1Terminated
- Sponsor
- Novartis
- Start
- May 2017
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, open-label trial of batoprotafib in non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC) and 2 more (2 arms), sponsored by Novartis. Primary endpoints: Number of participants with adverse events and serious adverse events up to 5 years, Number of participants with dose limiting toxicities up to 28 days and 2 more. Started May 2017; status: terminated.
02
Drugs
batoprotafib
03
Conditions
non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)head and neck squamous cell carcinoma (HNSCC)melanomagastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT03114319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114319.